Tirilazad
Chemical compound
- N07XX01 (WHO)
- (16α)-21-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]-16-methylpregna-1,4,9(11)-triene-3,20-dione
- 110101-66-1
N
- 104903
- 94673
Y
- YD064E883I
- D08606 Y
- ChEMBL1630578 N
- Interactive image
- O=C(CN4CCN(c2nc(nc(N1CCCC1)c2)N3CCCC3)CC4)[C@H]6[C@H](C)C[C@H]5[C@H]8C(=C/C[C@@]56C)\[C@]/7(/C=C\C(=O)\C=C\7CC8)C
InChI
- InChI=1S/C38H52N6O2/c1-26-22-31-29-9-8-27-23-28(45)10-12-37(27,2)30(29)11-13-38(31,3)35(26)32(46)25-41-18-20-43(21-19-41)34-24-33(42-14-4-5-15-42)39-36(40-34)44-16-6-7-17-44/h10-12,23-24,26,29,31,35H,4-9,13-22,25H2,1-3H3/t26-,29-,31+,35-,37+,38+/m1/s1Y
- Key:RBKASMJPSJDQKY-RBFSKHHSSA-NY
N
Y (what is this?) (verify)Tirilazad is a drug that has been proposed to treat acute ischaemic stroke. When tested on animal models, tirilazad protects brain tissue, and reduces brain damage. However, the drug fails to treat, and even worsens a stroke when studied on a human being.[1]
References
- ^ Bath PM, Iddenden R, Bath FJ, Orgogozo JM, et al. (Tirilazad International Steering Committee) (2001). "Tirilazad for acute ischaemic stroke". The Cochrane Database of Systematic Reviews (4): CD002087. doi:10.1002/14651858.CD002087. PMID 11687138.
- v
- t
- e
Other nervous system drugs (N07X)
- Tirilazad
- Arimoclomol§
- Mecasermin rinfabate†
- Riluzole
- Xaliproden
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
